Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06003153 · ClinicalTrials.gov registry record · Phase 4
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
A Phase 4 study of Type 2 Diabetes and Genetic Predisposition, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 125
- Enrollment target
- 1
- Study location
NCT06003153 is a Phase 4 study of Type 2 Diabetes and Genetic Predisposition that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 125 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06003153, a Phase 4 study of Type 2 Diabetes and Genetic Predisposition, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research study is to evaluate the pathophysiologic mechanisms by which genetic variation impacts response to an FDA-approved medication commonly used to treat type 2 diabetes called oral semaglutide (Rybelsus) and to characterize the physiological response to a mixed meal tolerance test (MMTT) before and after a 14-day treatment with oral semaglutide. The investigators will do this by measuring factors in the blood, such as sugars, fats, metabolites, and proteins, after eating a standardized breakfast meal at the first visit and after taking 14 doses of oral semaglutide over two weeks before the second study visit. The food (mixed meal breakfast) we will be studying is specially prepared to contain a set amount of protein, carbohydrates, and fat. The investigators hypothesize that understanding how the acute biochemical response to oral semaglutide differs by genetic variation will generate insight into drug mechanisms and type 2 diabetes pathophysiology.
Conditions Studied
Interventions
- DRUG oral semaglutide
- OTHER Mixed Meal Tolerance Test (MMTT)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2024-03-12 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06003153
The ClinicalTrials.gov registry entry for NCT06003153 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (89% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which oral semaglutide is the first listed.
NCT06003153 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06003153 about?
NCT06003153 is a clinical study titled "GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH". The goal of this research study is to evaluate the pathophysiologic mechanisms by which genetic variation impacts response to an FDA-approved medication commonly used to treat type 2 diabetes called oral semaglutide (Rybelsus) and to characterize the physiological response to a mixed meal tolerance ...
What is the current status of trial NCT06003153?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 125 participants. The study started on 2024-03-12. Estimated completion is 2027-05-31.
What conditions does trial NCT06003153 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Genetic Predisposition, Metabolic Diseases.
What interventions are being tested in trial NCT06003153?
The interventions under investigation include: oral semaglutide (DRUG), Mixed Meal Tolerance Test (MMTT) (OTHER).
Who is sponsoring clinical trial NCT06003153?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06003153 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 Diabetes
RECRUITING · Phase 4
-
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes
RECRUITING · Phase 4
-
Quantifying Hepatic Mitochondrial Fluxes in Humans
RECRUITING · Phase 4
-
DIALYSIS-TIR Study
ACTIVE NOT RECRUITING · Phase 4
-
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
ACTIVE NOT RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.